Should I buy or sell Science 37 stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNCE, but not buy additional shares or sell existing shares. View SNCE analyst ratings or view top-rated stocks .

When did Science 37's stock split?

Shares of Science 37 reverse split on the morning of Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

NASDAQ:SNCE

Science 37 (SNCE) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free SNCE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $5.75
▼
$5.75
50-Day Range: $5.68
▼
$5.75
52-Week Range: $3.73
▼
$12.96

Volume: N/A
Average Volume: 43,227 shs
Market Capitalization: $34.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Science 37 alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Science 37 Stock (NASDAQ:SNCE)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

SNCE Stock News Headlines

April 17, 2024 | markets.businessinsider.com

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

April 17, 2024 | globenewswire.com

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 12, 2024 | prnewswire.com

eMed completes tender offer for all outstanding shares of Science 37

February 27, 2024 | businesswire.com

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

February 12, 2024 | finance.yahoo.com

eMed commences tender offer for Science 37

February 10, 2024 | businesswire.com

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

February 10, 2024 | markets.businessinsider.com

Science 37 Initiates Cost-Cutting, Workforce Reduction Plan

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 4, 2024 | morningstar.com

Science 37 Holdings Inc SNCE

February 1, 2024 | benzinga.com

Science 37 Hldgs Stock (NASDAQ:SNCE) Dividends: History, Yield and Dates

January 31, 2024 | stockhouse.com

Shareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMed

January 30, 2024 | msn.com

Science 37 Issues Regulation FD Informational Disclosure

January 30, 2024 | msn.com

Science 37 Announces Upcoming Merger Agreement Execution

January 30, 2024 | realmoney.thestreet.com

Science 37 just downgraded at Craig-Hallum, here's why

January 29, 2024 | stockhouse.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Science 37 Holdings, Inc. Buyout

January 29, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Science 37 (SNCE), Avid Bioservices (CDMO)

January 29, 2024 | benzinga.com

Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher

January 29, 2024 | tmcnet.com

SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders

January 29, 2024 | finanznachrichten.de

Science 37, Inc.: Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

January 29, 2024 | marketwatch.com

Science 37 Shares Rise on Deal to Be Acquired

December 28, 2023 | seekingalpha.com

NDRA, LITM and SNCE among mid-day movers

December 13, 2023 | investorplace.com

SNCE Stock Earnings: Science 37 Hldgs Beats EPS, Beats Revenue for Q3 2023

December 13, 2023 | investorplace.com

SNCE Stock Earnings: Science 37 Hldgs Beats EPS, Beats Revenue for Q2 2023

December 13, 2023 | investorplace.com

SNCE Stock Earnings: Science 37 Hldgs Beats EPS, Beats Revenue for Q1 2023

December 12, 2023 | finance.yahoo.com

Science 37 Receives Top Honors in Everest PEAK Matrix®

December 5, 2023 | finance.yahoo.com

Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023

See More Headlines

Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Health Information Services
Sub-Industry: N/A
Current Symbol: NASDAQ:SNCE
CUSIP: N/A
CIK: 1819113
Web: www.lifesciacquisition.com
Phone: 984-377-3737
Fax: N/A
Employees: 460
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($21.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,990,000.00
Net Margins: -206.86%
Pretax Margin: -207.00%
Return on Equity: -83.09%
Return on Assets: -61.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.17
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $60.26 million
Price / Sales: 0.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $16.70 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 5,970,000
Free Float: 5,564,000
Market Cap: $34.33 million
Optionable: Not Optionable
Beta: 0.55

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. David Coman (Age 54)
CEO & Director
Comp: $796.13k
Ms. Christine A. Pellizzari J.D. (Age 56)
Chief Legal & Human Resources Officer and Secretary
Comp: $521.58k
Ms. Darcy Forman (Age 48)
Chief Delivery Officer
Comp: $550.58k
Mr. Mike Zaranek (Age 53)
Chief Financial Officer
Irena Lambridis
VP and Head of Quality Assurance & Compliance
Ms. Margie Gimbel Kooman
Vice President of Marketing & Communications
Mr. Drew Bustos
Chief Strategy & Marketing Officer
Mr. Jonathan Cotliar M.D. (Age 52)
Chief Medical Officer
Comp: $486.6k
Mr. Michael Shipton (Age 52)
Chief Commercial Officer
Mr. Tyler Van Horn
VP of Corporate Strategy & Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNCE Stock Analysis - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNCE, but not buy additional shares or sell existing shares.
View SNCE analyst ratings or view top-rated stocks.
When did Science 37's stock split?: Shares of Science 37 reverse split on the morning of Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

This page (NASDAQ:SNCE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Science 37 (SNCE) Stock Price, News & Analysis

About Science 37 Stock (NASDAQ:SNCE)

SNCE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SNCE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info